Methadone Dosing Recommendations for Treatment of Chronic Pain

− Methadone is a safe and effective long-acting opioid analgesic that is useful in managing chronic pain. − Although it has unique pharmacokinetic and pharmacodynamic properties, the general principles of dosing methadone are similar to those of other opioids. − In general, as with other opioids, methadone should be used as one aspect of a comprehensive pain management plan, as agreed upon by the practitioner and the patient. − Methadone is most easily titrated by using small initial doses or adjusting the initial dose according to the previous opioid dose. − A number of methods are available for titrating methadone using conversion ratios, as detailed below. However, titration should be based on patient response and not solely based on equianalgesic dosing tables. − Methadone should be initiated by or in consultation with a practitioner who has the relevant knowledge. If a practitioner or consultant with experience in using methadone for chronic pain is not available, then another long-duration opioid may be used until such consultation can be obtained. Background Methadone should be used when a strong opioid is needed and the patient has not achieved adequate pain relief on escalating doses of controlled-release morphine or has experienced intolerable adverse effects on controlled-release morphine. Commonly, nonsteroidal anti-inflammatory drugs and adjuvant agents (e.g., tricyclic antidepressants) should be used in combination with methadone. Methadone's duration of effect is not dependent upon a specialized delivery system, as is the case with transdermal fentanyl or sustained release formulations of morphine or oxycodone. It is the only long-duration opioid available as an oral solution.

[1]  G. Tucker,et al.  The pharmacokinetics of methadone in healthy subjects and opiate users. , 2003, British journal of clinical pharmacology.

[2]  R. Gebhardt,et al.  Conversion From Intrathecal Morphine to Oral Methadone , 2001, Regional Anesthesia & Pain Medicine.

[3]  F. Fulfaro,et al.  Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Kalso,et al.  Morphine and alternative opioids in cancer pain: the EAPC recommendations , 2001, British Journal of Cancer.

[5]  Mellar P. Davis,et al.  Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration , 2001, Supportive Care in Cancer.

[6]  G. Tucker,et al.  Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. , 2000, Addiction.

[7]  D. Bridge,et al.  The rediscovery of methadone for cancer pain management , 2000, The Medical journal of Australia.

[8]  N. Hagen,et al.  Methadone: outpatient titration and monitoring strategies in cancer patients. , 1999, Journal of pain and symptom management.

[9]  S. Mercadante,et al.  Rapid switching from morphine to methadone in cancer patients with poor response to morphine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  I. Trocóniz,et al.  Methadone: a review of its pharmacokinetic/pharmacodynamic properties. , 1999, Journal of pharmacological and toxicological methods.

[11]  E. Bruera,et al.  Role of methadone in the management of pain in cancer patients. , 1999, Oncology.

[12]  E. Bruera,et al.  Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. , 1999, Journal of pain and symptom management.

[13]  K. Foley,et al.  Methadone in cancer pain management: individualize dose and titrate to effect. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Brunelli,et al.  Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Makin,et al.  The use of methadone in cancer pain poorly responsive to other opioids , 1998 .

[16]  E. Bruera,et al.  Dose ratio between morphine and methadone in patients with cancer pain , 1998, Cancer.

[17]  E. Zecca,et al.  An update on the clinical use of methadone for cancer pain , 1997, Pain.

[18]  P. Narang,et al.  Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. , 1996, Drug and alcohol dependence.

[19]  E. Zecca,et al.  Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Bruera,et al.  Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine , 1996, Cancer.

[21]  J. Gardner-Nix Oral methadone for managing chronic nonmalignant pain. , 1996, Journal of pain and symptom management.

[22]  E. Bruera,et al.  Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain , 1995, Pain.

[23]  Kay Wright Therapeutics in Terminal Cancer, 2nd Edition R Twycross S Lack Therapeutics in Terminal Cancer, 2nd Edition Churchill Livingstone 238pp £12.95 0-443-04118-0 , 1990 .

[24]  D. Denson,et al.  Pharmacokinetics of Continuous Intravenous Infusion of Methadone in the Early Post‐Burn Period , 1990, Journal of clinical pharmacology.

[25]  L. Grochow,et al.  Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study , 1989, Pain.

[26]  J. Plummer,et al.  Estimation of methadone clearance: application in the management of cancer pain , 1988, Pain.

[27]  W. Colburn,et al.  Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain , 1987, Clinical pharmacology and therapeutics.

[28]  M. Cousins,et al.  A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer , 1986, Pain.

[29]  Levy Mh,et al.  Pain management in advanced cancer. , 1985, Seminars in oncology.

[30]  P. Hartvig,et al.  Clinical Evaluation of Oral Methadone in Treatment of Cancer Pain , 1982, Acta anaesthesiologica Scandinavica. Supplementum.

[31]  M. Kreek,et al.  Methadone disposition in patients with chronic liver disease , 1981, Clinical pharmacology and therapeutics.

[32]  G. Hanks,et al.  Patient-controlled dose regimen of methadone for chronic cancer pain. , 1981, British medical journal.

[33]  A. Schecter,et al.  Methadone use in patients with chronic renal disease. , 1980, Drug and alcohol dependence.

[34]  E. Änggård,et al.  Pharmacokinetics of methadone during maintenance therapy: Pulse labeling with deuterated methadone in the steady state , 1979, European Journal of Clinical Pharmacology.

[35]  D. Ettinger,et al.  Important clinical pharmacologic considerations in the use of methadone in cancer patients. , 1979, Cancer treatment reports.

[36]  P. Symonds Methadone and the elderly. , 1977, British medical journal.

[37]  N. Gerber,et al.  Clinical eftects and pharmacokinetics of racemic methadone and its optical isomers , 1977, Clinical pharmacology and therapeutics.

[38]  J. Volavka,et al.  Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment , 1975, Clinical pharmacology and therapeutics.

[39]  C. Inturrisi,et al.  Disposition of methadone in man after a single oral dose , 1972, Clinical pharmacology and therapeutics.

[40]  K. Wolff,et al.  Steady-state pharmacokinetics of methadone in opioid addicts , 2004, European Journal of Clinical Pharmacology.

[41]  J. Ufkes,et al.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts , 2004, European Journal of Clinical Pharmacology.

[42]  E. Änggård,et al.  Pharmacokinetics of methadone in methadone maintenance treatment: Characterization of therapeutic failures , 2004, European Journal of Clinical Pharmacology.

[43]  E. Änggård,et al.  Pharmacokinetics of methadone during maintenance treatment: Adaptive changes during the induction phase , 2004, European Journal of Clinical Pharmacology.

[44]  E. Bruera,et al.  Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  J. Morley,et al.  Comments on Ripamonti et al., Pain, 70 (1997) 109-115. , 1997, Pain.